← Back
$ANTX All transactions

AN2 Therapeutics, Inc.

D

$ Value

Shares

50,150

Price

Filed

Mar 23

Insider

Name

Eizen Joshua M

Title

See Remarks

CIK

0001949621

Roles

Officer

Transaction Details

Transaction Date

2026-03-19

Code

D

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. | The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. | On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. | The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Filing Info

Accession No.

0001193125-26-120210

Form Type

4

Issuer CIK

0001880438

Eizen Joshua M's History

Date Ticker Type Value
2026-03-19 ANTX A
2026-03-19 ANTX D
2026-03-19 ANTX A
2026-03-19 ANTX D
2026-02-20 ANTX A $0
2026-02-20 ANTX A $0
2026-01-06 ANTX $7K
2026-01-05 ANTX $18K
2025-11-04 ANTX $3K

Other Insiders at ANTX (90d)

Insider Bought Sold Last
Zakrzewski Joseph S 2026-03-19
Spigelman Melvin K 2026-03-19
Wong Stephanie 2026-03-19
Chanda Sanjay
Chief Development Officer
2026-03-19
FitzPatrick Margaret M 2026-03-19
Easom Eric
Chief Executive Officer
2026-03-19
Day Lucy
Chief Financial Officer
2026-03-19
Aziz Kabeer 2026-04-10
Readnour Robin Shane 2026-03-19
Martin Patricia A. 2026-04-10
Marks Gilbert Lynn 2026-04-10
Eizen Joshua M
See Remarks
2026-03-19
Williams Sarah Joanne
Principal Accounting Officer
$347 2026-03-03